Navigation Links
Biotech Pioneer Discusses Breakthrough in Osteoporosis Treatment

Deltanoid founder and CEO Hector DeLuca has discovered and characterized a promising chemically modified Vitamin D compound, 2MD, which reverses the effects of osteoporosis. In animal studies, 2MD increases bone growth while leaving blood calcium levels unchanged even at doses 3,000 times the level of other compounds.

According to DeLuca, Vitamin Ds main job is to regulate calcium levels......

Full article >>> s willing to acquire rights for technologies in very early stages of development. They now want to see proof of principle and more developed products before they agree to deals, he said.

As a result, Deltanoids strategy will focus on developing university technology to the stage where large pharmaceutical companies are then willing to sign on. Deltanoid will not market drugs or take them......

Full article >>>
'"/>

Source:wistechnology.com By John Keach 04/15/03


Related biology technology :

1. Biotech officials praise focus of new venture fund
2. Biotech executive books a career flight thats closer to home
3. Gala Biotech among companies sold for $3.3 billion
4. Biotech with Madison ties raises $21M in capital
5. Biotech firm uses live heart tissue in drug screens
6. Biotech talent drew venture-funded firm to Madison
7. Biotech firm has strokes, Alzheimers in its sights
8. 42 days until the 2006 Olympics of Biotechnology in Chicago
9. Biotech crops gaining acceptance, but their full promise has yet to be fulfilled
10. Biotech leads list of top U.S. companies to work for
11. Biotech flourishes in 2005 while Big Pharma is on the decline
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers ... research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of the latest paper by its Science Editor, Dr. Elisabeth Bik, in the ... Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her previous position ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
(Date:1/18/2017)... 2017  Caris Life Sciences, a leading innovator ... largest private funder of pancreatic cancer research, are ... impact of immunotherapy in the treatment of pancreatic ... to identify potential trial candidates based on biomarker ... and study investigators. The Lustgarten Foundation is a ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):